image-title

FOR IMMEDIATE RELEASE
January 12, 2022

Contact: Katie Edmiston | Marketing Manager
(813) 843-1629
Katie.Edmiston@ncoda.org


NCODA WELCOMES NEW EXECUTIVE COUNCIL MEMBERS

 

CAZENOVIA, NY – NCODA today announced the appointment of four new members to the Executive Council. With the growth of NCODA, the Executive Council has been instrumental in facilitating a strong path forward for patient-centered and collaborative oncology care.

“With leadership representatives from across the nation, the Executive Council will continue to help support NCODA’s Mission and commitment to providing better care to cancer patients. We are pleased to welcome these new Executive Council members,” said Randy Erickson, RN, BSN, MBA, CEO of Utah Cancer Specialists and Chair of the NCODA Executive Council. “They join at an exciting time as we continue to drive positive change in oncology care; always focused on our patients.”

“I am personally delighted to welcome such a strong group of new Executive Council members, and I look forward to serving with each of them in the coming year,” said Jim Schwartz, RPh, NCODA President. “The dedication from this group of leaders will bring diverse expertise and insight to the next chapter of NCODA.”

The new Executive Council members are:

  • Sam Abdelghany, PharmD, MHA, BCOP, Executive Director of Oncology Pharmacy Services, Smilow Cancer Hospital at Yale New Haven
    Prior to Sam’s current role, he was the Coordinator of the Investigational Drug Service, where he supported Yale investigators conducting NIH, pharmaceutical, or Yale-sponsored clinical studies. Sam has a Master of Health Care Administration degree from Ohio University and serves on various committees including the Yale University Institutional Review Board as the Chair of the Oncology Board.
  • Neal Dave, PharmD | Executive Director of Pharmacy | Texas Oncology
    Neal oversees both the oral and IV medications across all Texas Oncology locations, is currently on the US Oncology P&T Executive Committee and has been a member since 2018. Neal earned his PharmD degree from the University of Texas.
  • Stuart Genschaw, MHA, MBA | Chief Operating Officer | Cancer & Hematology Centers of Western Michigan
    Stuart leads a practice with numerous locations across West Michigan, is an active consultant and advisor to physician practices, and received his MHA from Western Michigan University with an MBA from the University of Colorado.
  • Luis Raez, MD, FACP, FCCP | Medical Director and Chief Scientific Officer | Memorial Cancer Institute
    Luis is the immediate past President of the Florida Society of Clinical Oncology (FLASCO) and is Co-Director of the MCI/FAU Florida Cancer Center designated by the Florida governor. Prior to joining Memorial Cancer Institute, Luis was an associate professor of Medicine, Epidemiology and Public Health, and Co-director of Thoracic Oncology at Sylvester Cancer Center.

NCODA Founder and Executive Director, Michael Reff, RPh, MBA said, “The field of oncology has shown continuous innovation and development of numerous anti-cancer therapies. Therefore, the need for a collaborative, consistent approach to cancer care is vital to ensuring the best possible outcomes for patients. I feel very privileged to be part of this group of leaders. The Executive Council knows that it’s imperative to bring positive change and advocacy, and so we work tirelessly each day for our patients!”

 

#####

About NCODA

NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit www.ncoda.org.

Read More
image-title

FOR IMMEDIATE RELEASE
January 3rd 2022

STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE
Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison
Phone: (919) 903-2057
Email: kevin.scorsone@ncoda.org
www.ncoda.org

GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS

 

Throughout 2021 NCODA highlighted states throughout the country that took great strides to regulate Pharmacy Benefit Managers. On the final day of 2021, Governor Kathy Hochul of New York signed Senate Bill 3762 into law that will regulate PBMs and help protect local pharmacies.

The aforementioned bill was referred to as the Pharmacy Rescue Package. The legislation had received nearly unanimous support from both the New York State Assembly and the New York State Senate. The new law will help reduce the cost of prescription drugs for patients by regulating the Pharmacy Benefit Managers. 

According to Governor Hochul, the landmark bill enshrines in statute the most comprehensive PBM regulatory structure in the country. The law requires licensure and registration of PBMs which will bring oversight by state regulators and increase transparency when PBMs are performing services for health plans and when dealing with covered individuals, pharmacies and providers.

There are a few PBM’s that control the majority of the prescription drug market and are focused solely on profits instead of patients. Some PBM practices have eliminated independent drug stores that were once pillars of our communities in New York State and limited patient access to local pharmacists. 

NCODA believes in a collaborative patient focused approach, one that we believe includes a revamping of the PBM system to make access to quality care and medication a priority for all patients.  The NYS bill will make patients the priority, and it will make medication more accessible and affordable to every patient in New York State who is battling cancer.

NCODA applauds Governor Hochul and the New York State Legislature for turning this bill into law. 



Read More
image-title

November 12, 2021

 

Statement From NCODA Legislative & Policy Advisory Committee
Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison
(919) 903-2057
kevin.scorsone@ncoda.org

FOR IMMEDIATE RELEASE

 

Comment On Proposed LCD DL37810

Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms:

Optimizing Management of Patients in Underserved and Minority Populations

 

CAZENOVIA, NY – NCODA would like to commend the Centers for Medicare and Medicaid Services (CMS) for initiating the proposed LCD DL37810 for Medicare beneficiaries with advanced solid tumors. As a patient-centered organization, we support the overall intent of LCD DL37810, which increases access to NGS technology and optimizes the management of patients with advanced solid tumors.

We would like to comment on the proposed indications and specific views documented in the Summary of Evidence listed in the proposed LCD in reference to Next Generation Sequence (NGS) Comprehensive Genomic Profile (CGP) testing. NCODA requests that the requirement:

“CGP NGS testing for patient with advanced cancer is reasonable and necessary only when more limited (i.e., individual analyte or targeted panel (5-50 genes)) testing is insufficient…”

in the “Proposed Indications” section be removed to avoid confusion regarding coverage to test for FDA approved indications. Tumor mutation burden (TMB) can only be detected using assays over 200 genes and TMB is listed as an FDA indication for eligibility of pembrolizumab for all solid tumors.

NCODA values CMS’s recognition of the benefits of RNA-based NGS. We agree with supporting both the use of RNA-based NGS and DNA-based NGS given existing technology platforms and current use of both technologies.

NCODA applauds the fact that “NGS CGP testing may especially benefit the 25% of patients with rare cancer types… and underserved minority populations with less access to tumor molecular profiling or off-label therapies.” This dedication to address cancer disparities and rare disease states by recommending NGS CGP testing to help address these populations is in desperate need. NGS CGP facilitates identification of novel uses of existing targeted therapies and/or eligibility for clinical trials with novel genetic alterations, attempting to address such populations.

At NCODA, we are patient-centered and always collaborative. We strive to provide leadership, expertise, quality standards, and forward-thinking solutions to oncology healthcare professionals across the country. While the oncology community has made progress to ensure equity in cancer care over the years, we believe the work is far from over. In addition to ensuring that all cancer patients receive quality care, NCODA believes in providing access to all regardless of status. These disparities need to be reduced and eventually eliminated. Again, we applaud CMS for initiating the proposed LCD DL37810 for Medicare beneficiaries, and we believe that this is a positive step in the right direction toward providing better care for cancer patients from underserved and/or minority populations.

# # #

 

About NCODA

NCODA is a leading nonprofit organization dedicated to empowering medically integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. For more information about NCODA, its Executive Council, and general updates, visit www.ncoda.org or follow @NCODAorg on Twitter.

Read More
image-title
Contact: Kevin Scorsone
NCODA Legislative & Policy Liaison
(919) 903-2057
kevin.scorsone@ncoda.org

Statement From NCODA Legislative & Policy Advisory Committee
October 28, 2021

Patients Are The Priority: A Call For A Medically Integrated Community

 

CAZENOVIA, NY – New York State is the home of NCODA, and at one time locally owned pharmacies were commonplace. But now a system that allows certain Pharmacy Benefit Mangers (PBMs) to wield their power has put these pharmacies on the brink of permanent extinction.

Over the summer, NCODA educated our membership about a New York State Legislature bill that was passed with support on both sides of the aisle. The bill would establish increased oversight, accountability, and transparency for all PBMs throughout New York State. Former Governor Andrew Cuomo vetoed a similar bill in 2019, but since his exit from office, the current PBM bill has a chance to finally be signed into law at the hands of current Governor Kathy Hochul.

NCODA will always put patients first and look for solutions that lead to a medically integrated community that can achieve sustainability for patients in the years to come. Consistent with NCODA’s history and guiding values, announced last week was a first-of-its-kind collaboration with NOCDA and Prime Therapeutics, a PBM that servers more than 33 million members. Prime’s new IntegratedRx™ Oncology Program coupled with NCODA’s Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program will allow for a revolutionary shift of streamlined delivery of oncology treatment. Read the full press release here. Going Beyond the First Fill within a medically integrated oncology practice has been proven to enhance patient compliance and satisfaction, quality of care delivered, and cost avoidance and waste reduction to the healthcare system.

It is our belief that the oncology landscape needs to always be evolving and making life better for our patients; that includes reforming PBMs. One thing we always ask of our legislature, our government and the elected officials who mold the landscape of patient access to care is to be accountable. Accountability is necessary and we must hold PBMs accountable and help them address a system that needs change.

There are certain PBMs that control much of the pharmacy market. They are focused on profit instead of patients and have deals in place that are focused on eliminating independent pharmacies that were once pillars of our communities in New York. NCODA believes in a collaborative, patient-focused approach; one that we believe could include a revamping of the PBM system to make access to quality care and medication a realization for all patients.

NCODA is encouraged by the progress that has been made in New York State with support to rein in a few rogue PBMs and their non-patient centric practices. We hope that New York will follow the lead of other states including Texas, where NCODA President Jim Schwartz, RPh, had significant influence in the successful passage of PBM legislation in the state. The NYS bill would make patients the priority, and it would make medication more accessible and affordable to every patient in the state who is battling cancer.

NCODA’s Legislative and Policy Advisory Committee (LPAC) will be discussing this topic during their upcoming Legislative Roundtable on November 30, 2021 at 7PM Eastern. If any progress is made regarding the NYS bill prior to that, we will be the first to inform our membership.

 

# # #

 

About NCODA

NCODA is a leading nonprofit organization dedicated to empowering medically integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. For more information about NCODA, its Executive Council, and general updates, visit www.ncoda.org or follow @NCODAorg on Twitter.

 

Read More
image-title

 

Media Contacts:

Jenine Anderson│Public Relations Manager
Jenine.Anderson@primetherapeutics.com

Suzi Baugh│850-545-4247
Suzi@sachsmedia.com

 

 

Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation

Accredited medically integrated pharmacies may become eligible to participate in Prime’s IntegratedRx™ – Oncology network

EAGAN, Minn. and CAZENOVIA, NY– Oct. 19, 2021 – Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM) serving more than 33 million members, will prefer for its IntegratedRx™  – Oncology program the new specialized accreditation from NCODA, the leading nonprofit association for the patient-centered medically integrated oncology community. This first-in-market accreditation – which aligns with Prime’s essential accreditation criteria – is a component of required credentialing for IntegratedRx – Oncology.

IntegratedRx – Oncology streamlines the treatment pathway for members and providers through its best-in-care integrated dispensing model. With IntegratedRx, members can receive their medicine through the oncology clinic’s integrated pharmacy, where the provider and pharmacist are part of the same team, allowing for direct lines of communication. This end-to-end coordination across the treatment pathway helps improve adherence, shortens time to dispense, and creates a better patient outcome and provider experience from the first fill to the last fill.

NCODA recently announced its new Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program. The program, based on compliance with the ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing, focuses on enhanced patient care and quality of services.  NCODA is committed to empowering medically integrated pharmacies to deliver the highest level of performance that brings sustainability and value for all stakeholders. This program achieves the quadruple aim goals of improved clinician experience, better outcomes, lower costs, and improved patient experience. The key areas of focus include medication adherence, patient education and safety, cost avoidance and waste reduction, continuous quality improvement, financial assistance and patient satisfaction.

“Current accreditation standards don’t take into account the advantages of integrated pharmacy dispensing, said Joseph Leach, M.D., chief medical officer for Prime and a practicing oncologist. “Prime prefers NCODA’s MIP accreditation as it meets our quality requirements while reducing the burden associated with some broad accreditations, especially for oncology-specific pharmacies. It’s a perfect fit for the IntegratedRx dispensing model.”

Elizabeth Bell, director of medically integrated pharmacy accreditation for NCODA, said, “NCODA sees the IntegratedRx – Oncology program as a groundbreaking initiative. Allowing credentialed and accredited medically integrated oncology pharmacies to go beyond the first fill provides better patient outcomes and lower cost to the patient, practice, health plan and employer. Our patient-centered accreditation program was designed specifically for medically integrated oncology pharmacies and aligns perfectly with the IntegratedRx – Oncology program.”

Leach and Bell will introduce the accreditation to the medically integrated oncology community Oct. 22 at the NCODA Fall Summit in Scottsdale, Ariz.

About Prime Therapeutics

Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime provides total medicine management solutions for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 33 million people. It is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. For more information visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.

About NCODA

NCODA, Inc. is a 501(c)(3) organization. Our Mission is to empower the medically integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. For more information about NCODA’s Executive Council and general updates, visit www.ncoda.org.

###

Read More